ArticleScience advances2018

Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations.

Jaesung P Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.